CDK4 and cancer: Multiple preclinical studies support the hypothesis that CDK4/6i can improve the efficacy of standard chemotherapy treatments (such as paclitaxel and cisplatin) in TNBC and other cancer types by inducing apoptosis or potentiating DNA damage and causing increased cell death (11–16).